Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

University of Oxford-Sichuan University Huaxi Joint Centre for Gastrointestinal Cancer, a new international collaboration led by Prof. David Kerr (Radcliffe Department of Medicine, University of Oxford) and Prof. Li Yang (Sichuan University) was launched today, Friday 15 May 2020.

None

Over the next 5 years this new centre seeks to develop an integrated cancer plan with a focus on gastrointestinal cancer, underpinned by high quality basic, translational and clinical cancer research.

The intention is to develop one team based across two sites, with an operating and governance system that will drive the exchange of ideas, which is crucial to academic development and alleviating the burden that cancer places on societies across the world.

The Centre will seek to build a portfolio of multi-disciplinary teams drawing from both organizations. These teams and their projects will enable scientists and clinicians to learn from each other and apply their expertise for the benefit of cancer patients in both nations. The establishment of a bilateral researcher exchange program will drive the delivery of these.

Read the full story on the Cancer Research UK Oxford Centre website

 

Similar stories

Major grant to strengthen research and benefit patients

Oxford University Hospitals (OUH) has made a grant of £11.5 million to the University of Oxford, which the University will match with other funding, to allow the development of major clinical research facilities which have the potential to support the introduction of innovative and ground-breaking treatments for patients.

Dr Lennard Lee awarded ACP McElwain Prize for contributions to medical oncology

Dr Lee (Department of Oncology) received the award to acknowledge his contributions during the COVID-19 pandemic, through the establishment of the UK Coronavirus Cancer Monitoring Project.

Oxford joins forces with 11 universities to launch social impact investment fund

The University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.

Ivermectin to be investigated as a possible treatment for COVID-19 in the PRINCIPLE trial

From today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world’s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.